Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

People in Oxford who have osteoarthritis of the knee are being invited to take part in a national charity-funded clinical trial to find a more effective treatment.

Fiona Watt with PROMOTE trial
Fiona Watt with PROMOTE trial

The Arthritis Research UK clinical trial aims to find up to 160 people to take part around the country, at least eight patients will be recruited at the Nuffield Orthopaedic Centre, Oxford.

The trial will establish if a drug called methotrexate, commonly taken by people with rheumatoid arthritis, can also be effective in treating osteoarthritis: a completely different condition.

Osteoarthritis is a common condition of the joints, affecting around six million people in the UK, and caused largely by degeneration of cartilage at the ends of bones, and also inflammation, leading to pain and stiffness.

"Current treatments for knee osteoarthritis are limited in that they only work for short periods and are not suitable for many people," explained rheumatologist Dr Fiona Watt, who is leading the local arm of the trial.

"As a result, they often live with severe pain and have significant difficulty in carrying out their normal day-to-day activities. There is therefore an urgent need to find new and better ways of managing their pain."

Methotrexate is successfully and widely used to treat inflammation in rheumatoid arthritis, which is a serious auto-immune condition.

Recent studies have suggested that inflammation is also important in causing pain in osteoarthritis. Pilot studies which showed that 37% of patients with knee osteoarthritis who took methotrexate had a 40% reduction in their pain.

The clinical trial, run at the Nuffield Orthopaedic Centre by researchers from the Arthritis Research UK Centre for Osteoarthritis Pathogenesis, NDORMS, University of Oxford will recruit people with moderate to severe osteoarthritis of the knee, who are not getting benefit from traditional treatments such as painkillers. Half of those recruited will take methotrexate for 12 months and the other half will take a placebo tablet. Patients will also complete a questionnaire every three months.

To find out more please contact Angela Nauth, recruitment officer at the OA trials office at the University of Leeds, where the study is based, on 0113 3924965 or email oatrials@leeds.ac.uk

Similar stories

Neutrophil molecular wiring revealed: transcriptional blueprint of short-lived cells

Researchers publish the first blueprint of transcriptional factors that control neutrophil-driven inflammation in Nature Immunology.

NDORMS joins research partnership to understand links between overlapping long-term conditions

The links between different long-term health conditions will be explored in new research funded with a £2.5million grant from the Medical Research Council.

NDORMS researchers awarded grant for study on the effects of COVID-19 vaccines on long COVID

A team of NDORMS researchers including Doctor Annika Jödicke and Doctor Victoria Strauss have been awarded NIHR funding to carry out a study into the effects of different COVID-19 vaccines on long COVID.

New therapeutic targets identified in the treatment of psoriatic arthritis

Researchers identify two inflammatory-driving proteins, osteopontin and CCL2, highly expressed in psoriatic arthritis joints.

Researchers show the role of cilia in cartilage health

New research shows that disrupting primary cilia in juvenile, adolescent and early adulthood in cartilage stops it maturing correctly, making it more prone to thinning and the potential for osteoarthritis (OA) in later life.

New research could improve quality of life for Psoriatic Arthritis patients

Professors Laura Coates and Dani Prieto-Alhambra will take major roles in a new European Commission project to develop innovative personalised treatment options for people affected by psoriatic arthritis.